Neurological Autoimmune DiseasesPhase 1NCT07021209
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
A Phase 1 study testing GT719 Injection in people with Neurological Autoimmune Diseases, run by Grit Biotechnology at 1 site in China.
Trial summary
This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Neurological Autoimmune Diseases
- What is being tested?
- GT719 Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- 14 Jan 2025to 13 Jan 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.
- Expected survival period>12 weeks.
- Any previous systemic treatment must have undergone at least 4 weeks or 5 half lives (whichever is shorter) by the time the participant plans to receive the study treatment.
Who cannot join
- History of organ transplantation, splenectomy, and allogeneic or autologous stem cell transplantation.
- History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.
- Received systemic corticosteroids at a dose of ≥10 mg/day prednisone equivalent within 7 days prior to GT719 infusion, except for inhaled corticosteroids.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei
Daishi Tian, +8613607178809, tiands@tjh.tjmu.edu.cn
Wei Wang
About this study
Official title: A Single-arm, Open-label, Phase I Clinical Study of GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.
- Conditions
- Neurological Autoimmune Diseases
- Being tested
- GT719 Injection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GT719 InjectionBiological
GT719 Injection
| Study group | Role | What they receive |
|---|---|---|
| GT719 Injection treatment group | Experimental | GT719 Injection Receives: Biological: GT719 Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence and severity of adversed events
To characterize the safety profile of GT719 in patients with recurrent/refractory antibody-mediated neurological immune diseases as measured by the incidence and severity of adverse events
Measured: 24 months
Secondary outcomes (1)
Pharmacokinetics of GT719 cells
Survival time of GT719 cells after infusion of GT719 Injection
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2025
- Study start14 Jan 2025
- Primary completion13 Jan 2028 (estimated)
- Study completion13 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurological Autoimmune DiseasesStudies of the same condition, open and under way.
- More trials run by Grit BiotechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Grit Biotechnology
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Tongji Hospital
- Responsible party
- Sponsor
- Investigators
- Wei Wang, Principal investigator, Tongji HospitalDaishi Tian, Principal investigator, Tongji HospitalChuan Qin, Principal investigator, Tongji Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07021209
- Sponsor's protocol ID
- GRIT-CD-CHN-719-002
- Status last verified
- Sep 2026
- First submitted
- 29 May 2025
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-arm, Open-label, Phase I Clinical Study of GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
- ClinicalTrials.gov ID
- NCT07021209
- Acronym / sponsor ID
- GRIT-CD-CHN-719-002
- Conditions
- Neurological Autoimmune Diseases
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Grit BiotechnologyIndustry (pharma, biotech, devices)
- Collaborators
- Tongji Hospital
- Study start
- 14 Jan 2025 (actual)
- Primary completion
- 13 Jan 2028 (estimated)
- Study completion
- 13 Jan 2028 (estimated)
- First posted
- 13 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| GT719 Injection treatment group | Experimental | Biological: GT719 InjectionGT719 Injection |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.
- Expected survival period>12 weeks.
- Any previous systemic treatment must have undergone at least 4 weeks or 5 half lives (whichever is shorter) by the time the participant plans to receive the study treatment.
Key exclusion criteria (3 listed)
- History of organ transplantation, splenectomy, and allogeneic or autologous stem cell transplantation.
- History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.
- Received systemic corticosteroids at a dose of ≥10 mg/day prednisone equivalent within 7 days prior to GT719 infusion, except for inhaled corticosteroids.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GT719 InjectionGT719 Injection | Biological | GT719 Injection treatment group |
Primary outcome
Incidence and severity of adversed events
Time frame: 24 months
To characterize the safety profile of GT719 in patients with recurrent/refractory antibody-mediated neurological immune diseases as measured by the incidence and severity of adverse events
1 secondary outcome
Pharmacokinetics of GT719 cells
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Neurological Autoimmune Diseases
RecruitingObservational study
Natural History of Type 1 Interferonopathies: Insights From a European Cohort
Genetic Disease, Immune Dysfunction
RecruitingEarly Phase 1
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
Neurological Autoimmune Diseases
RecruitingObservational study
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Post-Acute COVID-19 Syndrome, ME/CFS
RecruitingObservational study
Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions
Genetic Diseases, Immune Dysfunction
Not yet recruitingEarly Phase 1
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
Neurological Autoimmune Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Wei Wang principal investigator
Tongji Hospital
Daishi Tian principal investigator
Tongji Hospital
Chuan Qin principal investigator
Tongji Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing GT719 Injection in people with Neurological Autoimmune Diseases, run by Grit Biotechnology at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Daishi Tian (+8613607178809, tiands@tjh.tjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence and severity of adversed events (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026; AzTrials last refreshed its copy on 7 Nov 2026.